4
Changes in Ownership
Kiniksa Pharmaceuticals International, plc Filed Acc 0001415889-25-011992
CHIEF COMMERCIAL OFFICER sold 10,122 shares at $28.00 ($283,416)
- CHIEF COMMERCIAL OFFICER acquired 10,122 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-02 | Option exercise 10b5-1 | +3,850 | $17.76 | $68,376 | 13,265 | D |
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-02 | Sale 10b5-1 | −3,850 | $28.00 | $107,800 | 9,415 | D |
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-05 | Option exercise 10b5-1 | +6,272 | $17.76 | $111,391 | 15,687 | D |
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-05 | Sale 10b5-1 | −6,272 | $28.00 | $175,616 | 9,415 | D |
| Derivatives | |||||||
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-01 | Grant or award · Performance Share Unit 10b5-1 | +4,976 | 4,976 | D | ||
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-01 | Grant or award · Performance Share Unit 10b5-1 | +5,225 | 5,225 | D | ||
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-01 | Grant or award · Performance Share Option 10b5-1 | +8,043 | 8,043 | D | ||
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-01 | Grant or award · Performance Share Option 10b5-1 | +8,303 | 8,303 | D | ||
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-02 | Option exercise · Share Option 10b5-1 | −3,850 | 33,661 | D | ||
| Moat Ross CHIEF COMMERCIAL OFFICER | 2025-05-05 | Option exercise · Share Option 10b5-1 | −6,272 | 27,389 | D | ||
| Open-market sales · 10,122 sh · avg $28.00 · $283,416 | |||||||
Loading xslF345X05/form4-05052025_080547.xml…